Choksi Laboratories Ltd

Choksi Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 10 Sep 2026, reflecting notable improvements in its technical indicators and valuation metrics. Despite flat recent financial performance, the company’s stock has demonstrated strong relative returns over the short and medium term, prompting a reassessment of its investment appeal within the healthcare services sector.

Choksi Laboratories Ltd, a micro-cap player in the healthcare services sector, has seen its investment rating downgraded from Hold to Sell as of 9 September 2026. This adjustment reflects a nuanced assessment across four critical parameters: quality, valuation, financial trend, and technicals. Despite some attractive valuation metrics and institutional interest, the company’s flat recent financial performance and mixed technical signals have weighed on its overall outlook.

Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid a backdrop of strong price gains and mixed financial metrics, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks.

Choksi Laboratories Ltd, a micro-cap player in the healthcare services sector, has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, valuation metrics, and institutional interest despite flat recent financial performance. This upgrade, effective from 26 August 2026, signals cautious optimism amid mixed fundamentals and market underperformance.

Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Sell to Hold as of 19 Aug 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite some lingering concerns over long-term fundamentals. The company’s stock price has shown resilience with a 1.10% gain on the day, signalling renewed investor interest amid mixed market conditions.

Choksi Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Choksi Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The healthcare services company’s technical outlook has improved to mildly bullish, prompting a reassessment of its near-term prospects, even as financial trends and valuation metrics present a mixed picture.

Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 29 July 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, and a challenging valuation backdrop, signalling caution for investors amid ongoing market underperformance.

Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 22 July 2026. This change is primarily driven by a shift in technical indicators, even as the company continues to grapple with weak financial fundamentals and underperformance relative to the broader market.

Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has been downgraded from a Sell to a Strong Sell rating as of 17 July 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, and weak fundamental metrics, signalling heightened risks for investors amid a challenging market environment.

Choksi Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Choksi Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Choksi Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Choksi Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Choksi Laboratories Ltd., a contract testing and analytical services provider, reported a sharp recovery in quarterly profit for Q4 FY26, with net profit surging to ₹1.03 crores—a dramatic 232.26% increase quarter-on-quarter and 11.96% year-on-year. However, beneath this headline improvement lies a concerning narrative of operational challenges, elevated debt levels, and weak returns on capital that continue to constrain the micro-cap company's investment appeal. Trading at ₹140.00 with a market capitalisation of ₹98.00 crores, the stock has gained 29.21% over the past year but remains 40.85% below its 52-week high of ₹236.70.

Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 20 May 2026. This change reflects a nuanced shift primarily driven by technical indicators, even as the company’s fundamental and financial metrics remain subdued. The stock’s recent price surge of 12.42% and improved technical signals contrast with flat quarterly financials and weak long-term fundamentals, presenting a complex picture for investors.